'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma-A multicentre, retrospective study.
Matthew R WilsonEuan HaynesKatrina ParsonsDavid HopkinsElizabeth RobertsonGraeme FergusonDaire QuinnJim MurrayWendy OsborneMike LeachPamela McKayPublished in: British journal of haematology (2023)
Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients. We modified the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone), whereby bleomycin and etoposide were removed and cyclophosphamide dose was reduced, for older patients with co-morbidities. Here we present data from the first 41 patients treated with 'ACOPP' across 3 centres, demonstrating that it can be delivered, with a favourable toxicity profile (TRM 2%) and promising efficacy (2-year PFS and OS, 73% (95% CI: 52-94) and 93% (95% CI: 80-100) respectively).
Keyphrases
- hodgkin lymphoma
- end stage renal disease
- low dose
- high dose
- ejection fraction
- newly diagnosed
- physical activity
- locally advanced
- pulmonary fibrosis
- community dwelling
- chronic kidney disease
- peritoneal dialysis
- clinical trial
- drug delivery
- oxidative stress
- electronic health record
- radiation therapy
- study protocol
- cross sectional
- cancer therapy
- chemotherapy induced
- double blind
- artificial intelligence